ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.2335
-0.0246 (-9.53%)
At close: Nov 19, 2025, 4:00 PM EST
0.2370
+0.0035 (1.50%)
After-hours: Nov 19, 2025, 7:24 PM EST
ProPhase Labs Revenue
ProPhase Labs had revenue of $-1.80M in the quarter ending September 30, 2025, a decrease of -157.06%. This brings the company's revenue in the last twelve months to $6.24M, up 464.43% year-over-year. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$6.24M
Revenue Growth
+464.43%
P/S Ratio
1.41
Revenue / Employee
$64,969
Employees
96
Market Cap
9.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
| Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
| Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
| Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
| Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRPH News
- 3 hours ago - ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET. - GlobeNewsWire
- 1 day ago - ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19 - GlobeNewsWire
- 2 days ago - ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals - GlobeNewsWire
- 21 days ago - ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology - GlobeNewsWire
- 22 days ago - ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts - GlobeNewsWire
- 26 days ago - ProPhase Labs to Present at the 2025 ThinkEquity Conference - GlobeNewsWire
- 4 weeks ago - ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology - GlobeNewsWire